KRAS G12S

Clinical trials for KRAS G12S explained in plain language.

Never miss a new study

Get alerted when new KRAS G12S trials appear

Sign up with your email to follow new studies for KRAS G12S, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

New pill targets Hard-to-Treat cancers in early trial

Disease control Recruiting now

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

Matched conditions: KRAS G12S

Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control

Last updated Jun 27, 2026 13:01 UTC

KRAS G12S

Get alerted when new KRAS G12S trials appear

New pill targets Hard-to-Treat cancers in early trial